Literature DB >> 16014669

Refractory adult onset Still's disease and hypersensitivity to non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors: are biological agents the solution?

E H J G Aarntzen, P L C M van Riel, P Barrera.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16014669      PMCID： PMC1755234          DOI： 10.1136/ard.2005.042945

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  4 in total

1.  A long story begun with a simple sore throat.

Authors:  Giuseppina Pisano; Paola Bonara; Paolo Rietti; Lorena Airaghi; Luigi Sinigaglia; Giovanni Boccoli; Larry Burdick; Marta del Medico; Edoardo Pulixi; Fabio Silini; Alessandra Gandolfi; Silvia Fargion
Journal:  Intern Emerg Med       Date:  2010-07-22       Impact factor: 3.397

2.  Successful treatment of refractory adult onset Still's disease with rituximab.

Authors:  K Ahmadi-Simab; P Lamprecht; C Jankowiak; W L Gross
Journal:  Ann Rheum Dis       Date:  2006-08       Impact factor: 19.103

3.  Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial.

Authors:  George D Kalliolias; Panagiotis E Georgiou; Ioannis A Antonopoulos; Andrew P Andonopoulos; Stamatis-Nick C Liossis
Journal:  Ann Rheum Dis       Date:  2007-06       Impact factor: 19.103

4.  Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study.

Authors:  Katerina Laskari; Athanasios G Tzioufas; Haralampos M Moutsopoulos
Journal:  Arthritis Res Ther       Date:  2011-06-17       Impact factor: 5.156
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.